« Back
Home /
LBH589 (Panobinostat)

LBH589 (Panobinostat)

Item no.	M1748-1g
Manufacturer	AbMole
CASRN	404950-80-7
Amount	1g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	>99.0%
Citations	ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth. Thakur, et al . PLoS One. 2012,7(8):e43671. PMID: 22916295 . The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Vallo, et al . Invest New Drugs. 2012 Jul 17. PMID: 22801803 . LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice. Wang, et al . Biol Blood Marrow Transplant. 2012 Aug,18(8):1182-1190. PMID: 22698484 . HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi, et al . Pancreatology. 2012 Mar,12(2):146-55. PMID: 22487525 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NVP-LBH589, Panobinostat
Similar products	LBH589, NVP-LBH589, Panobinostat
Available
Target Information	HDAC
Molecular Weight	349, 43
Solubility	DMSO 59 mg/mL
Bioactivity information	LBH589 (Panobinostat) is a novel broad-spectrum HDAC inhibitor for MOLT-4 and Reh cells with IC50 of 5 and 20 nM, respectively.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1748-1g-safety-datasheet.pdf